Results 251 to 260 of about 692,775 (346)
Global Perspectives in Plastic Surgery: View of Plastic Surgeons From Peru. [PDF]
Bustamante A, Diaz J, de Pawlikowski W.
europepmc +1 more source
Factors affecting the low demand and the penetration of life insurance in Burundi
Nina Uwiteka Bettina
openalex +1 more source
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi +12 more
wiley +1 more source
Patient Priorities for Coverage of New Antihypertensive Drugs: A Discrete Choice Experiment in China. [PDF]
Chen J +7 more
europepmc +1 more source
Financial Development and Life Insurance Demand in Sub-Sahara Africa
Osama Ose Iyawe, Ifuero Osad Osamwonyi
openalex +2 more sources
Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon +2 more
wiley +1 more source
Sexual Health Needs and Physician-Patient Interaction Experiences Among Postoperative Radical Prostatectomy Patients in China: A Qualitative Study. [PDF]
Zhu H +9 more
europepmc +1 more source
Objective The purpose of this study was to determine the benefit of a behaviorally designed incentive program and glucocorticoid injections in reducing symptoms and promoting physical activity in patients with knee osteoarthritis (KOA). Methods This was a pragmatic, multisite, factorially designed, blinded, randomized clinical trial.
Joshua F. Baker +17 more
wiley +1 more source

